Nikita Patel cuts Bacil Pharma stake to 17% in open-market sale
The largest non-promoter shareholder sold 2.27% of the zero-revenue nano-cap. Bacil Pharma's market cap sits at ₹68 crore.
— 2 earlier stories on Bacil Pharma Ltd. →What's new
- Nikita Hiren Patel sold 326,104 shares (2.27%) on June 8-9 via open market.
- Her holding fell from 19.44% to 17.17% of the company's equity.
- The transaction was disclosed to the BSE under SEBI's substantial acquisition rules.
Why this matters
Bacil Pharma reports zero operating revenue. Its ₹68 crore market cap rests on other income and speculation. When the single largest outside investor trims a material stake, it is a direct signal about conviction. The filing gives no reason for the sale.
What we're watching
- Whether Patel continues to offload her remaining 17.17% stake.
- Any explanatory statement from the company or the seller.
- The stock's price and volume reaction in subsequent sessions.
The full read
Nikita Patel, Bacil Pharma's largest non-promoter shareholder, sold 2.27% of the company's equity. The open-market transactions on June 8 and 9 trimmed her stake from 19.44% to 17.17%. Bacil Pharma is a nano-cap with a market capitalisation of about ₹68 crore and ₹0 in operating revenue. The company's latest quarter showed ₹0 in sales. For a business with no revenue, the stock price is a speculative bet. A significant stake reduction by the biggest outside investor is a direct signal about their conviction. The filing provides no reason for the sale. Against a backdrop of zero revenue, that silence is the most concrete detail.
Questions answered
- Who sold the shares and by how much did their stake fall?
- Non-promoter Nikita Hiren Patel sold 326,104 shares, reducing her holding from 19.44% to 17.17% of Bacil Pharma's equity.
- Why is a 2.27% sale by this shareholder material?
- Patel was the largest non-promoter in a nano-cap company with no operating revenue. For a stock whose value is detached from business fundamentals, a stake cut by its biggest outside holder is a significant move that demands attention.
- What are the company's latest financials?
- For the quarter ended March 2026, Bacil Pharma reported ₹0 in sales and a net profit of ₹1 crore. For the full year, it had zero revenue from operations.
- When did the sale occur and when was it disclosed?
- The open-market transactions happened on June 8 and 9, 2026. The filing was submitted to the BSE the next day, June 10.
Bacil Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BACPHAR →- 11 Jun 2026 · 10:31 AM IST Nikita Patel cuts Bacil Pharma stake to 17% in open-market sale
- 19d ago Bacil Pharma remains non-operational as annual profit masks losses
- 19d ago Bacil Pharma reports zero revenue for FY26